One of the most important mantras for any pre-revenue biotech company is
to raise money when you can, not just when you need it. Celldex Therapeutics (NASDAQ: CLDX )
is following that advice, leveraging the ongoing biotech bull market
and the boom in interest for cancer immunotherapies to raise another
$171 million in cash.
Follow this link to continue:
Celldex Uses the Immunotherapy Boom to Build Its War Chest
No comments:
Post a Comment